MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the Attack on Pearl Harbor this weekend at Phoenix Raceway for the season finale.
The special paint scheme of the Nurtec ODT 51 car depicts a special tribute to the 80th Anniversary of Pearl Harbor on December 7, 2021. One hundred percent of the proceeds from the Nine Line Apparel Remembering 80 Years of Infamy T-shirt will be donated directly to Best Defense Foundation, to help send sixty World War II veterans to Hawaii next month for a week-long ceremony honoring those who lost their lives, and those who defended the front lines when our country needed it the most.
"Throughout the year we have been honored to give back to the men and women in uniform, as well as honor those who have served our country and paid the ultimate sacrifice," commented team owner Rick Ware. "Having great partners like Nurtec ODT and Nine Line Apparel who continue to drive the importance of our military and those who have served is humbling. Paying tribute to the 80th Anniversary Attack on Pearl Harbor and honoring those who tragically lost their lives that day is an important and special way to close out the 2021 NASCAR season and our Military Salutes program."
"We have seen firsthand the impact migraine has on our active duty service members, veterans and their families. Through this sponsorship of the Rick Ware Racing team, we have been able to raise awareness of this debilitating disease and how relief may be available with Nurtec ODT. It is important to us as a company to support people with migraine and those who have dedicated their lives for the greater good. We salute the World War II veterans and the sacrifices they and their families have made," said Graham Goodrich, Senior Vice President of Marketing, Biohaven Pharmaceuticals.
"We couldn't be more honored to partner again with Rick Ware Racing and Nurtec ODT to support our nation's veterans," said Rich Caponi, Chief Revenue Officer at Nine Line Apparel. "Being able to support the Best Defense Foundation's initiative to get these WWII heroes back to Pearl Harbor to remember, honor, and bring closure is something that we are humbled and proud to be a part of."
The Best Defense Foundation was founded in 2018 by former NFL Linebacker, Donnie Edwards. The Foundation honors and celebrates our veterans from past conflicts, including, WWII, Korea, Vietnam and those who have recently retired. As a monumental anniversary approaches in December, The Best Defense Foundation is scheduled to bring sixty World War II veterans back to Pearl Harbor for a "Day That Shall Remain in Infamy." The veterans will depart from Dallas, Texas on December 3rd, and participate in a four-day event that will conclude in a special ceremony on December 7th. Through the Foundation, all expenses will be paid, including airfare and travel accommodations for both the veterans and their caregivers.
"We are honored to bring veterans back to their battlefields to rekindle the brotherhood and provide closure on such an important time for themselves and the world. Our programs are 100% for the veterans and we pride ourselves on quality programs to fulfill our mission of taking care of the ones who took care of us," commented Donnie Edwards, Executive Director of Best Defense Foundation.
In addition to Rick Ware Racing's participation in next month's events in Hawaii, the No. 51 car will be present in The Pearl Harbor Memorial Parade, that is produced by Historic Programs and has been designated as one of "America's Living Memorials." This annual Parade commemorates the Anniversary of the Attack on Pearl Harbor by Saluting our Veterans, their families and active military members, while remembering and honoring those who lost their lives 80 years ago. Historic Programs produces truly meaningful events by uniting generations of Americans - bringing our young students to the places where history was made to pay tribute and learn directly from our history makers. These programs will educate, honor and inspire Americans for generations to come.
The season finale at Phoenix Raceway is set for November 7th and will be televised live on NBC. For more information on Rick Ware Racing, visit www.wareracing.com, or follow along on social media; Twitter, Facebook, Instagram.
About Rick Ware Racing
With a rich and extensive history, Rick Ware Racing has been part of the racing fabric in the USA for over 30 years. The team currently fields a team in NASCAR Cup Series, NASCAR Xfinity Series, NTT INDY CAR Series and NASCAR Pinty's Series. The team most recently claimed the 2020 Asian Le Mans Series Am Championship.
About Nine Line Apparel
Founded in 2012 by Army Captain and former Special Operations Air Mission Commander Tyler Merritt, Nine Line Apparel is a patriotic lifestyle brand based out of Savannah, Georgia. Nine Line is known for their patriotic designs, and as a give-back organization that supports our nation's veterans and first responders through the Nine Line Foundation and other non-profit initiatives. To learn more, visit ninelineapparel.com.
About Best Defense Foundation
What began as a simple conversation during a chance meeting with a WWII veteran has turned into Donnie's life mission. Inspired by stories from his grandfather, a Pearl Harbor survivor, Donnie has worked tirelessly to take WWII veterans back to the battlefields where they served.
To date, the Foundation has taken over 100 WWII veterans on battlefield return programs to remember their fallen comrades and gain closure of a time in their life that had an impact on the world. Through our Battlefield Return programs, WWII veterans travel all over the world including to Normandy, the Netherlands, Germany, Belgium, Pearl Harbor, Iwo Jima, Guam, Saipan, and Tinian for commemorations.
In addition to the Battlefield Return Program, the Foundation created a Transition Program to help retired Special Forces operators return to civilian life and connect with the community around them. Utilizing Donnie's NFL network, we bring the professional athlete world together with special forces to help each other grow.
Finally, the last mission of the Best Defense Foundation is to educate future generations about the heroism and sacrifices of those who have served through the preservation of their stories. To date, we have interviewed over 200 WWII veterans with a video archive of more than 2000 hours of first hand accounts of the history that is taught today. Our Education Initiative curates a curriculum from this media content and uses it to preserve the legacy of those who sacrificed for us.
About NURTEC ODT
NURTEC ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily to treat or every other day to help prevent migraine attacks. For more information about NURTEC ODT, visit www.nurtec.com. The most common adverse reaction was nausea and abdominal pain/indigestion. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Indication
NURTEC ODT orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine. It is not known if NURTEC ODT is safe and effective in children.
Important Safety Information|
Do not take NURTEC ODT if you are allergic to NURTEC ODT (rimegepant) or any of its ingredients.
Before you take NURTEC ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:
- have liver problems,
- have kidney problems,
- are pregnant or plan to become pregnant,
- breastfeeding or plan to breastfeed.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NURTEC ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take NURTEC ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with NURTEC ODT.
The most common side effects of NURTEC ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of NURTEC ODT. Tell your HCP if you have any side effects.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1–800–FDA–1088 or report side effects to Biohaven at 1–833–4NURTEC.
Please click here for full Prescribing Information and Patient Information.
About Biohaven
Biohaven (NYSE: BHVN) is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.
Forward-looking Statement
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven's management about NURTEC ODT as an acute treatment for patients with migraine and preventive treatment for migraine. Factors that could affect these forward-looking statements include those related to: Biohaven's ability to effectively commercialize NURTEC ODT, delays or problems in the supply or manufacture of NURTEC ODT, complying with applicable U.S. regulatory requirements, the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, the potential commercialization of Biohaven's product candidates, the potential for Biohaven's product candidates to be first in class or best in class therapies and the effectiveness and safety of Biohaven's product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Biohaven's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 1, 2021, and Biohaven's subsequent filings with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC.
Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer
[email protected]
Media Contact:
Mike Beyer
Sam Brown Inc.
[email protected]
312-961-2502
Rick Ware Racing Contact:
Kate Fegley
[email protected]
704-607-0372
SOURCE Biohaven Pharmaceutical Holding Company Ltd.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article